Novel transcript, antisense to SPNS3 (ENSG00000262823)

This target is a *natural antisense transcript* overlapping the SPNS3 gene. Antisense RNAs often play regulatory roles in gene expression by modulating the transcription, stability, or processing of sense transcripts[3][5][6]. There is increasing evidence that antisense transcription can influence chromatin architecture, epigenetic marks, and transcription dynamics in both yeast and humans, for example by modulating histone acetylation near promoters[1]. For SPNS3, a protein involved in sphingolipid and lipid transport, the presence of an antisense transcript may regulate its expression pattern and impact cellular lipid signaling[2][4]. However, antisense transcripts in general are not considered direct therapeutic targets such as receptors or enzymes; instead, they are functional RNAs involved in the complex regulation of gene expression and epigenetic states[3][1][5][6]. No direct drug interactions, clinical biomarker roles, or safety concerns are associated with this antisense transcript. The functional significance and disease associations remain largely unexplored. If you need structured information on SPNS3 itself (the protein-coding gene), it could be considered a transporter and may have distinct therapeutic relevance[2][4], but the "novel transcript, antisense to SPNS3" is a regulatory RNA, not a canonical drug target.

Other names

ENSG00000262823antisense to SPNS3NAT-SPNS3 (inferred as a typical NAT abbreviation, not canonical)